Bisacodyl

證據等級: L5

預測適應症: 10 個

Bisacodyl: From Constipation to Exercise-Induced Malignant Hyperthermia

One-Sentence Summary

Bisacodyl is a well-established stimulant laxative used for the management of constipation and bowel preparation prior to colonoscopy or surgical procedures. The TxGNN model predicts it may be effective for Exercise-Induced Malignant Hyperthermia, with a prediction score of 97.69%; however, no clinical trials or published literature currently support this direction, and the mechanistic rationale is considered biologically implausible.

Quick Overview

Item	Content
Original Indication	Constipation; pre-procedure bowel preparation (standard pharmacological use; no Singapore HSA registration on file)
Predicted New Indication	Exercise-Induced Malignant Hyperthermia
TxGNN Prediction Score	97.69%
Evidence Level	L5
Singapore Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data from DrugBank is not available for this report. Based on established pharmacological knowledge, Bisacodyl is a stimulant laxative that acts directly on the colonic mucosa. It inhibits water and electrolyte reabsorption, stimulates the myenteric plexus, and accelerates colonic transit — effects localised entirely to the gastrointestinal tract.

Exercise-induced malignant hyperthermia (MH) is a genetic disorder of skeletal muscle calcium regulation driven by loss-of-function or gain-of-function mutations in the RYR1 or CACNA1S genes. During physical exertion or heat stress, these mutations cause uncontrolled calcium release from the sarcoplasmic reticulum, triggering a life-threatening hypermetabolic crisis characterised by rigidity, hyperthermia, and rhabdomyolysis.

There is no identifiable mechanistic bridge between Bisacodyl's colonic action and the calcium channelopathy underlying exercise-induced MH. The two pathologies involve entirely distinct anatomical locations, receptor systems, and signalling pathways. The elevated TxGNN score is most likely attributable to indirect graph noise around "hyperthermia"-related nodes in the knowledge graph, rather than any true pharmacological connection. This prediction is considered biologically implausible and is flagged as a model artefact.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Singapore Market Information

Bisacodyl is not currently registered with the Singapore Health Sciences Authority (HSA). No product authorisation records are on file.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN model score (97.69%), this prediction lacks any mechanistic plausibility — Bisacodyl acts exclusively on the colonic mucosa while exercise-induced MH is a genetically-driven skeletal muscle calcium channelopathy — and is supported by zero clinical trials or published literature. The absence of Singapore market registration further removes any existing safety dataset to draw upon.

To proceed, the following is needed:

Mechanism of action confirmation via DrugBank API to rule out any indirect pharmacological pathways not yet documented
Preclinical data demonstrating any effect of Bisacodyl (or related stimulant laxatives) on RYR1/CACNA1S channel function or skeletal muscle calcium homeostasis
Full Singapore package insert or equivalent (e.g., UK/EU SmPC, US label) for complete safety profile, contraindications, and drug interaction assessment
Independent pharmacological expert review to formally assess biological plausibility before any further resource allocation
Consideration of alternative drug candidates for exercise-induced MH with more mechanistically coherent TxGNN predictions
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.